In a 2022 phase II trial of non-small cell lung cancer (NSCLC) patients, perioperative immunonutrition elevated serum IgG, IgA, IgM, and CD4+ counts while increasing pre-Alb levels (30). The gene discussed is CD79A; the disease is non-small cell lung carcinoma.